Notable Labs Notable Labs
  • ABOUT
    • ABOUT US
    • OUR MISSION
    • LEADERSHIP
    • BOARD OF DIRECTORS
  • PLATFORM & PIPELINE
    • PREDICTIVE PRECISION MEDICINE PLATFORM
    • VOLASERTIB & FOSCICLOPIROX
  • NEWS
    • All News
    • Investor Events and Presentations
    • Press Releases
    • Scientific Presentations & Publications
    • Content Search
  • Investors
    • Investor Overview
    • SEC Filings
    • Financials
    • Governance
    • IR Contacts
    • Partnership
    • Stock Information
  • Careers
  1. You are here:  
  2. Scientific Posters
  3. RARA Pathway Activation Biomarkers in Study SY-1425-201 Define a New Subset of AML and MDS Patients and Correlate with Myeloid Differentiation Following Ex Vivo SY 1425 Treatment
Details
Category: Scientific Presentations
01.Jul

RARA Pathway Activation Biomarkers in Study SY-1425-201 Define a New Subset of AML and MDS Patients and Correlate with Myeloid Differentiation Following Ex Vivo SY 1425 Treatment

We developed an epigenetic approach to profile the gene regulatory landscape of primary AML/MDS patient samples. A novel patient subset defined by RARA pathway activation was identified by super-enhancers (SEs) at the RARA and IRF8 gene loci.

Viewable PDF:

CLICK HERE

 

To learn more, share ideas, or join our mission.
Contact us today!

CONNECT WITH US

  • PRIVACY POLICY
  • TERM OF USE
  • COOKIE STATEMENT
  • INVESTOR OVERVIEW
  • CAREERS
  • CONTACT US

Copyright © 2023 Notable

We use cookies on our website. Some of them are essential for the operation of the site, while others help us to improve this site and the user experience (tracking cookies). You can decide for yourself whether you want to allow cookies or not. Please note that if you reject them, you may not be able to use all the functionalities of the site.

Accept Decline
Cookie Statement